Talk to sales Try for Free
Paul C. Tumeh

Paul C. Tumeh

Internal Medicine Intern

Followers of Paul C. Tumeh682 followers
location of Paul C. TumehSan Francisco Bay Area

Connect with Paul C. Tumeh to Send Message

Connect

Connect with Paul C. Tumeh to Send Message

Connect

  • Timeline

  • About me

    Founder & CEO at BioGraph 55, Inc.

  • Education

    • College of William and Mary

      1996 - 2000
      B.S., Biology and Psychology

    • University of Southern California, Los Angeles

      2001 - 2005
      Doctor of Medicine - MD

      Activities and Societies: Medical Scholar in Hematology/Oncology 2002 Medical Scholar in Biochemistry 2003 Dean’s Scholar for Year III 2004 Dean’s Scholar for Year IV 2005 Medical Scholar in Neurosciences 2005 Medical Faculty Scholarship 2005 Alpha Omega Alpha Medical Honor Society 2005

  • Experience

    • Penn Medicine, University of Pennsylvania Health System, Department of Internal Medicine

      Jan 2005 - Jan 2006
      Internal Medicine Intern

    • University of Pennsylvania School of Medicine, Division of Hematology/Oncology

      Jan 2006 - Jan 2007
      Postdoctoral Fellow in Cancer Biology

    • UCLA Medical Center, Division of Hematology/Oncology

      Jan 2007 - Jan 2008
      Postdoctoral Fellow in Tumor Immunology

    • Harbor-UCLA Medical Center

      Jan 2008 - Jan 2011
      Resident Physician

    • Department of Medicine, David Geffen School of Medicine at UCLA

      Jan 2011 - Jan 2016

      • Health Sciences Assistant Clinical Professor – In Residence

        Jan 2014 - Jan 2016

      • Health Sciences Assistant Clinical Professor

        Jan 2012 - Jan 2014

      • Health Sciences Clinical Instructor

        Jan 2011 - Jan 2012

    • BioGraph 55

      Aug 2016 - now
      Chief Executive Officer

      Founder and CEO of BioGraph 55, Inc., a preclinical stage biotech company focused on delivering novel B-cell therapies to oncology and autoimmunity markets to address huge unmet clinical needs. To date, Paul has raised $20M from Red Tree Venture Capital, Pfizer Ventures, Alexandria Real Estate Equities, Panacea Venture and Pathway Bioventures. He has lead the company from inception to the present day including team build-out, drug discovery, development and preclinical R&D, and defining the path to IND. He is a translational immuno-oncology expert with publications in Nature and New England Journal of Medicine, an NIH Scientific Review Group member and previously, an NIH-funded investigator, recipient of the Damon Runyon Clinical Investigator Award, and principal investigator for the Howard Hughes Medical Institute (HHMI) Medical Research Fellows Program. Paul previously served as a scientific advisory board member for Alpine Immune Sciences, Inc, Illumina, Inc, and the Harry J. Lloyd Charitable Trust: Melanoma Research Grant Program. He has served as a reviewer for Nature Medicine, Nature Communications, Nature Protocols, Cancer Research, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Journal of the National Cancer Institute, Molecular Oncology, Journal of Translational Medicine, and OncoImmunology. Show less

  • Licenses & Certifications

    • PHYSICIAN AND SURGEON A

      Medical Board Of California

  • Honors & Awards

    • Awarded to Paul C. Tumeh
      Damon Runyon Clinical Investigator Award (PI TUMEH, funding period 2015 - 2018*) Damon Runyon Cancer Research Foundation Apr 2015 Project Title: Determining the role of PD-L1+ myeloid cells during PD-1 blockade in melanomaRole: Principal Investigator Background: The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. *Due to my anticipated transition into… Show more Project Title: Determining the role of PD-L1+ myeloid cells during PD-1 blockade in melanomaRole: Principal Investigator Background: The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. *Due to my anticipated transition into biotech, I requested that this award be transferred back to the Damon Runyon Cancer Research Foundation. Show less
    • Awarded to Paul C. Tumeh
      American Skin Association Research Grant (PI TUMEH, funding period 2014-2015) American Skin Association Dec 2014 Project Title: Developing an In-Situ Proteomic Profiling Approach to Characterize the Melanoma Microenvironment During PD1 BlockadeRole: Principal InvestigatorProject: Project: This research grant provided support to investigators focused on one of five disease-specific research areas. Melanoma represents one of the five disorders. The aim of this grant is to establish a protocol that combines laser-capture microdissection followed by proteomic profiling to enrich for cell-types… Show more Project Title: Developing an In-Situ Proteomic Profiling Approach to Characterize the Melanoma Microenvironment During PD1 BlockadeRole: Principal InvestigatorProject: Project: This research grant provided support to investigators focused on one of five disease-specific research areas. Melanoma represents one of the five disorders. The aim of this grant is to establish a protocol that combines laser-capture microdissection followed by proteomic profiling to enrich for cell-types restricted in time and space and understand the interactions between two cell-types (CD8+PD1+ T- cells and PD-L1+CD11b+ macrophages). Show less
    • Awarded to Paul C. Tumeh
      STOP Cancer Research Career Development Award (PI TUMEH, funding period 2014 - 2016) STOP CANCER Nov 2014 Project Title: “Determining the role of innate immune receptors in PD-L1+ macrophages at the invasive tumor margin in terms of initiating a Type I IFN response in tumors responding to anti-PD1 therapy.” Role: Principal InvestigatorProject: STOP CANCER grants were given to the most promising scientists at UCLA’s Jonsson, USC Norris and City of Hope Comprehensive Cancer Centers. Awardees were selected each year based on nominations of each cancer center’s internal peer review… Show more Project Title: “Determining the role of innate immune receptors in PD-L1+ macrophages at the invasive tumor margin in terms of initiating a Type I IFN response in tumors responding to anti-PD1 therapy.” Role: Principal InvestigatorProject: STOP CANCER grants were given to the most promising scientists at UCLA’s Jonsson, USC Norris and City of Hope Comprehensive Cancer Centers. Awardees were selected each year based on nominations of each cancer center’s internal peer review recommendations and are awarded to assist in developing their research program. The objective of this project was to identify and analyze how cells of the innate immune system (macrophages, dendritic cells, neutrophils) impact the tumor microenvironment during PD-1 blockade in responding versus progressing tumors. Show less
    • Awarded to Paul C. Tumeh
      Determining the role of CD301+ tumor-associated macrophages in adaptive immune resistance during PD-1 blockade in advanced melanoma (PI TUMEH, funding period 2014-2016) Sponsored research agreement with biotech Oct 2014 Role: Principal InvestigatorProject: This sponsored research agreement was focused on understanding the immunoregulatory role of CD301+ tumor-associated macrophages in enforcing adaptive resistance during PD-1 blockade. Biomarker analysis and functional studies will be performed.
    • Awarded to Paul C. Tumeh
      Development of the Vectra Platform for Multiparametric Phenotypic Analysis of the Tumor Microenvironment (PI TUMEH, funding period 2014-2016) sponsored research agreement Oct 2014 Role: Principal InvestigatorProject: This project was focused on establishing a multiparametric phenotyping approach within the context of tissue architecture to understand the immunoregulatory role of PD-L1+ tumor-associated macrophages at the invasive margin in enforcing adaptive resistance before PD-1 blockade (T-cell inhibitory, M2 phenotype) and determining if this cell-type switches to an M1 phenotype (T-cell stimulatory) during PD1 blockade in Responders.
    • Awarded to Paul C. Tumeh
      Kure It Investigator Award (PI TUMEH, funding period 2014 - 2016) Kure It Cancer Research Jul 2014 Kure It’s mission is to be the leader in granting funds to scientists researching kidney cancer and other underfunded cancers. These researchers receive “seed monies” to explore innovative research projects. Learn more about these brilliant individuals that have made advances in eradicating cancer.Project Title: “Predicting Response to Anti-PD1 Therapy in Advanced Melanoma.”Role: Principal InvestigatorProject: We have recently discovered a distinct niche (i.e., spatial… Show more Kure It’s mission is to be the leader in granting funds to scientists researching kidney cancer and other underfunded cancers. These researchers receive “seed monies” to explore innovative research projects. Learn more about these brilliant individuals that have made advances in eradicating cancer.Project Title: “Predicting Response to Anti-PD1 Therapy in Advanced Melanoma.”Role: Principal InvestigatorProject: We have recently discovered a distinct niche (i.e., spatial organization, density, phenotype, and unique cell-interconnectedness) within the tumor microenvironment that predicts response to anti-PD1 therapy. This project builds on these findings and aims to validate our predictive model that we have established in collaboration with Dr. David Elashoff’s lab. Show less
    • Awarded to Paul C. Tumeh
      Howard Hughes Medical Institute (HHMI) Medical Research Fellows Program (PI TUMEH, funding period 2013 - 2014) Howard Hughes Medical Institute Jul 2013 Title: “Determining the Functional Role of PDL-1+CD68+ Myeloid Derived Cells during PD-1 Blockade”Role: Principal Investigator and MentorBackground: The Medical Research Fellows Program was designed to encourage the development of future medical-scientists by providing a year of full-time, mentored laboratory research training to medical, dental, and veterinary students with a demonstrated interest in and commitment to biomedical research, but who were not enrolled in an MD/PhD (or… Show more Title: “Determining the Functional Role of PDL-1+CD68+ Myeloid Derived Cells during PD-1 Blockade”Role: Principal Investigator and MentorBackground: The Medical Research Fellows Program was designed to encourage the development of future medical-scientists by providing a year of full-time, mentored laboratory research training to medical, dental, and veterinary students with a demonstrated interest in and commitment to biomedical research, but who were not enrolled in an MD/PhD (or equivalent) program.The program enabled students to be immersed in a high-impact, intensive research experience at a critical time in their professional education, before making plans for residency or postdoctoral training. Unique aspects of the program included national and regional professional development activities, mentorship by physician-scientists, interaction with HHMI investigators, and integration into a community of like-minded peers. Show less
    • Awarded to Paul C. Tumeh
      Jonsson Comprehensive Cancer Center (JCCC) Early Investigator Fund (PI TUMEH, funding period 2012 - 2016) UCLA Jonsson Comprehensive Cancer Center Aug 2012 Project Title: “Tumor-associated CD8+ T-cells and Anti-Tumor Responses during PD-1 blockade.”Role: Principal InvestigatorProject: This fund was awarded to early investigators to facilitate development of their research program. This project aims to characterize how responding and progressing tumors during PD-1 blockade differentially evolve and to identify and characterize cell types that mediate anti-PD-1 mediated tumor regression.
    • Awarded to Paul C. Tumeh
      NIH K08 1K08AI091663-01 (PI TUMEH, funding period 2011 - 2016) NIH Sep 2011 Title: “Determinants of tumor response to PD-1 blockade in melanoma”Role: Principal InvestigatorProject: This K08 award was focused on identifying cellular and molecular determinants within the spatial context of the tumor microenvironment in tumors that do not respond to PD-1 blockade.